Premium
Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis
Author(s) -
Garrido Colmenero Cristina,
Blasco Morente Gonzalo,
Tercedor Sánchez Jesús
Publication year - 2015
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12592
Subject(s) - medicine , atopic dermatitis , scorad , cumulative dose , ciclosporin , severity of illness , dermatology , chemotherapy , disease , dermatology life quality index
Cyclosporine A (CyA) is a systemic therapy used to control severe atopic dermatitis ( AD ) in children, but its use may be associated with serious side effects. Intermittent short‐course therapy has been used to minimize these risks without the loss of clinical benefits. We conducted a 20‐week study using intermittent short‐course CyA therapy in five patients with severe AD and a Scoring Atopic Dermatitis ( SCORAD ) score >40. The result was a reduction in the cumulative dose of CyA and serum CyA level, which allows for a longer duration of CyA treatment and decreases the risk of relapse in patients with severe AD .